Quemliclustat

Phase 3Small molecule

Quemliclustat is one of 189 small molecule programs targeting Locally Advanced Bladder Urothelial Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

188

Competitors

Pipeline

Status by Indication[3][1]

Indication

Locally Advanced Bladder Urothelial CarcinomaNot yet recruiting

Gastrointestinal Tract MalignanciesActive, not recruiting

Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruiting

Biliary Tract CarcinomaActive, not recruiting

Lung CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaRecruiting

Metastatic Prostate CancerRecruiting

Pancreatic AdenocarcinomaRecruiting

MetabolismActive, not recruiting

Locally Advanced Bladder Urothelial CarcinomaPreclinical

Not yet recruiting

Gastrointestinal Tract MalignanciesPhase 2

Active, not recruiting

Metastatic Pancreatic Ductal AdenocarcinomaPhase 3

Active, not recruiting

Biliary Tract CarcinomaPhase 2

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Recruiting

Metastatic Prostate CancerPhase 2

Recruiting

Pancreatic AdenocarcinomaPhase 2

Recruiting

MetabolismPhase 1

Active, not recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

33 2

Opdivo

Bristol-Myers Squibb

Phase 3

20 3

Tagrisso

AstraZeneca

Phase 3

19 4

Beyfortus

BeiGene

Phase 3

10 5

Yervoy

Bristol-Myers Squibb

Phase 3

10 6

Abraxane

Bristol-Myers Squibb

Phase 3

7 7

Alunbrig

Takeda

Phase 3

4 8

Alecensa

Roche

Phase 3

3 9

DATROWAY

Daiichi Sankyo

Phase 3

2 10

Verzenio

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Pancreatic Adenocarcinoma

NCT05688215

Q2 2027

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06048484

Phase 2Active, not recruiting

Gastrointestinal Tract Malignancies

NCT05329766

Q3 2027

Phase 2Active, not recruiting

Biliary Tract Carcinoma

NCT06048133

Q4 2027

Phase 2Active, not recruiting

Lung Cancer

NCT05676931

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Completed· Arcus Biosciences logo

Arcus Biosciences·Phase 1/2·NCT04381832·173 enrolled

Metastatic Prostate Cancer1 trial

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

Recruiting·CCatherine Spina·Phase 2·NCT05915442·23 enrolled

Lung Cancer1 trial

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 2·NCT05676931·400 enrolled

Metabolism1 trial

Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24)

Active, not recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 1·NCT07364214·8 enrolled

Pancreatic Adenocarcinoma1 trial

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Recruiting·JJonsson Comprehensive Cancer Center·Phase 1/2·NCT05688215·56 enrolled

5 more indications

Pancreatic Ductal Adenocarcinoma1 trial

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

Recruiting·GGulam Manji·Phase 2·NCT06048484·60 enrolled

Locally Advanced Bladder Urothelial Carcinoma1 trial

A Phase Ib/II Study to Evaluate the Safety and Efficacy of Enfortumab Vedotin Plus Pembrolizumab in Combination With Quemliclustat in Unresectable Locally Advanced and Metastatic Urothelial Carcinoma

Recruiting·FFred Hutchinson Cancer Center·Preclinical·NCT07667335·27 enrolled

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 3·NCT06608927·610 enrolled

Gastrointestinal Tract Malignancies1 trial

A Phase 2 Trial to Evaluate the Safety and Efficacy of Combination Therapies in Patients With Advanced Upper Gastrointestinal Tract Malignancies (EDGE-Gastric)

Active, not recruiting· Arcus Biosciences logo

Arcus Biosciences·Phase 2·NCT05329766·332 enrolled

Biliary Tract Carcinoma1 trial

Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First-line Treatment of Advanced Biliary Tract Cancers (QUIC)

Active, not recruiting·NNataliya Uboha·Phase 2·NCT06048133·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Quemliclustat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Quemliclustat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Quemliclustat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Arcus Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Arcus Biosciences

Quemliclustat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Prostate Cancer1 trial

Metastatic Prostate Cancer1 trial

Lung Cancer1 trial

Metabolism1 trial

Pancreatic Adenocarcinoma1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Locally Advanced Bladder Urothelial Carcinoma1 trial

Metastatic Pancreatic Ductal Adenocarcinoma1 trial

Gastrointestinal Tract Malignancies1 trial

Biliary Tract Carcinoma1 trial

References

Drug Info

Quick Facts

Related News